Clinical Trial

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without Type 2 Diabetes Mellitus (T2DM) (Part 1), and the safety, tolerability, and PD of multiple doses of ARO-ALK7 in adult participants with obesity with and without T2DM, either as monotherapy or in combination with tirzepatide (Part 2).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-10 -> 2027-02 2026-07-09
minor Completion pushed: 2026-10 -> 2027-02 2026-07-09
Trial Details
NCT Number NCT06937203
Lead Sponsor Arrowhead Pharmaceuticals
Conditions Obesity, Diabetes Mellitus, Type 2
Enrollment 150 participants
Start Date 2025-05-09
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-08